A number of firms have modified their ratings and price targets on shares of Edwards Lifesciences (NYSE: EW) recently:

  • Edwards Lifesciences was downgraded by analysts at RBC Capital from a “top pick” rating to an “outperform” rating.
  • Edwards Lifesciences had its price target lowered by analysts at Piper Jaffray from $118.00 to $105.00. They now have an “overweight” rating on the stock.
  • Edwards Lifesciences had its price target lowered by analysts at UBS AG from $110.00 to $95.00. They now have a “neutral” rating on the stock.
  • Edwards Lifesciences had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • Edwards Lifesciences had its price target lowered by analysts at Barclays Capital from $90.00 to $85.00. They now have an “overweight” rating on the stock.
  • Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Goldman Sachs.
  • Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $109.00 price target on the stock.

Edwards Lifesciences traded down 0.85% on Thursday, hitting $87.05. Edwards Lifesciences has a 1-year low of $61.59 and a 1-year high of $110.79. The company has a market cap of $10.073 billion and a price-to-earnings ratio of 42.03.

Edwards Lifesciences Corporation (Edwards Lifesciences) is engaged in the science of heart valves and hemodynamic monitoring.